DGAP-News
Sangui BioTech International Inc.: SastoMed closes contracts with distribution partners in six additional markets in Eastern Europe
DGAP-News: Sangui BioTech International Inc. / Key word(s): Market
launch
Sangui BioTech International Inc.: SastoMed closes contracts with
distribution partners in six additional markets in Eastern Europe
03.02.2015 / 15:00
---------------------------------------------------------------------
SanguiBioTech: SastoMed closes contracts with distribution partners in six
additional markets in Eastern Europe
Witten, Germany, February 3, 2015 - SastoMed GmbH has informed Sangui of
having closed contracts for initiating distribution and sales of the Sangui
developed dressing material Granulox in six Eastern European countries. In
2015 the three Baltic countries will join the family of Granulox
territories along with the Czech Republic, Slovakia and Hungary.
Like in three Scandinavian markets it will be an enterprise belonging to
the Mediq group which will start initiating the distribution in Estonia,
Latvia and Lithuania. Mediq Eesti OÜ (www.mediq.ee) is a wholesale company
which has been successfully trading medical and health care products
throughout the Baltic countries for many years. Its core business is in
medical products and laboratory equipment. A care a.s.
(http://www.acare.cz/cs) was entrusted with the Granulox business in the
Czech Republic and in Slovakia. The company specializes in medical
products, in particular in the fields of wound management, interventional
cardiology and radiology as well as neuroradiology. Halley Pharma Ltd.
(http://halleypharma.com) will look after the Hungarian market in which
they already distribute a wide array of other wound management products.
In total there are distribution partnerships in place now for 40 countries
worldwide, in 24 of which Granulox is already available for doctors and
patients. In the remaining 16 countries market entry is scheduled for the
next few months after the training of the sales force will have been
completed, or after the local registration procedures will have been
accomplished, respectively, which is the case in some Central and South
American countries.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de
Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes
no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise
---------------------------------------------------------------------
03.02.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
318529 03.02.2015
SanguiBioTech: SastoMed closes contracts with distribution partners in six
additional markets in Eastern Europe
Witten, Germany, February 3, 2015 - SastoMed GmbH has informed Sangui of
having closed contracts for initiating distribution and sales of the Sangui
developed dressing material Granulox in six Eastern European countries. In
2015 the three Baltic countries will join the family of Granulox
territories along with the Czech Republic, Slovakia and Hungary.
Like in three Scandinavian markets it will be an enterprise belonging to
the Mediq group which will start initiating the distribution in Estonia,
Latvia and Lithuania. Mediq Eesti OÜ (www.mediq.ee) is a wholesale company
which has been successfully trading medical and health care products
throughout the Baltic countries for many years. Its core business is in
medical products and laboratory equipment. A care a.s.
(http://www.acare.cz/cs) was entrusted with the Granulox business in the
Czech Republic and in Slovakia. The company specializes in medical
products, in particular in the fields of wound management, interventional
cardiology and radiology as well as neuroradiology. Halley Pharma Ltd.
(http://halleypharma.com) will look after the Hungarian market in which
they already distribute a wide array of other wound management products.
In total there are distribution partnerships in place now for 40 countries
worldwide, in 24 of which Granulox is already available for doctors and
patients. In the remaining 16 countries market entry is scheduled for the
next few months after the training of the sales force will have been
completed, or after the local registration procedures will have been
accomplished, respectively, which is the case in some Central and South
American countries.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de
Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes
no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise
---------------------------------------------------------------------
03.02.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
318529 03.02.2015
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte